Trump threatens 200% tariffs on generic drugs in 2028, wants manufacturing to move to US
The recent announcement by former President Donald Trump regarding tariffs on generic drugs has sparked significant concern within the pharmaceutical industry, particularly among Indian manufacturers. Generic drugs constitute over 90% of prescriptions in the U.S., with nearly half of these originating from India. Trump’s proposal includes a phased tariff plan that would escalate to 200% by 2029 if foreign manufacturers do not relocate production to the U.S. This has led to immediate reactions in the stock market, with major Indian pharmaceutical companies experiencing declines. Analysts have characterized the stock market response as a "kneejerk reaction," noting that the feasibility of such a plan is questionable. The challenges of reshoring generic drug production to the U.S. are substantial, given the existing cost advantages of manufacturing in countries like India. The proposed tariffs would apply to all countries supplying generics, not just India, which complicates the landscape further. Experts suggest that while some companies may explore onshoring high-margin products, the overall economic viability of establishing large-scale generic manufacturing facilities in the U.S. remains doubtful. As the industry navigates these uncertainties, many firms are already looking to diversify their markets beyond the U.S., seeking opportunities in emerging economies to mitigate risks associated with potential tariff implementations.
Commenti